A large UK-based retrospective cohort study found that initiating metformin within 90 days of COVID-19 diagnosis reduced the risk of Long COVID by 64% in overweight and obese adults. The findings suggest metformin may offer a low-cost preventive option pending confirmation from randomized trials.